Bromodeoxyuridine (BrDU) assay confirmed that RG@M-γ-CD CNP treatment markedly reduced the proliferation of CRC cells compared with other treatments (6.9 ± 3.3% and 12.8 ± 4.5% for CT26 and HT29, respectively). This evidence concerns the gene CNP and colorectal carcinoma.